Mineral supplement
Magnesium Glycinate
Magnesium glycinate has an app-listed half-life of about 6 hours, and a plasma half-life for it was not identified in PubMed.
Magnesium Glycinate after one dose: 50% at ~6 h, 25% at 12 h, 12.5% at 18 h.
Drawn from the half-life in the app's model, ~6 h. The model's figures
- Compound
- Magnesium Glycinate
- Symbol
- MG
- Family
- Supplements
- Parts
- 13
- References
- 8
- Checked
- Last reviewed . Sources are listed below.
Overview
Schuster and colleagues describe magnesium bisglycinate as "a chelated compound combining magnesium with glycine".1 The trials below name the compound magnesium bisglycinate (Schuster; Pajuelo), magnesium diglycinate (Schuette) or magnesium glycinate (a Mayo Clinic registry entry and Maddirevula and colleagues), so the name on each study is given as its authors wrote it.1,2,3,4,5 The human evidence reviewed here is four published randomised trials and two registry entries marked completed whose entries give no results data.1,2,3,5,4,6 Schuster and colleagues (Leibniz University Hannover and Murdoch University, Nature and Science of Sleep, 2025) compared 250 mg a day of elemental magnesium as bisglycinate with placebo for 4 weeks in adults reporting poor sleep.1 Pajuelo and colleagues (Nutrients, 2024) and Schuette and colleagues (University of Chicago, 1994) measured absorption as the main outcome and also recorded tolerability.2,3 The app grades the evidence for magnesium glycinate as strong; the sleep trial itself reports a small effect size on self-reported outcomes.1
How it works
Sources in this part
Schuster and colleagues write that "magnesium is postulated to be the main contributor to the observed effects" and that "glycine may provide complementary benefits".1 As background the same authors cite in vitro work in which magnesium "at physiologically relevant concentrations potentiates GABAA receptor activity, thereby enhancing inhibitory neurotransmission"; this is cited laboratory work, not a result of their trial.1 They also write that "magnesium bisglycinate has been shown to increase brain magnesium levels at high doses in mice, whereas its effects on muscle magnesium levels appear to be minimal", which is a finding in mice.1 On absorption, Schuette and colleagues write that their data "support the suggestion that some portion of magnesium diglycinate is absorbed intact, probably via a dipeptide transport pathway", from a trial in 12 patients with ileal resections.3 Schuster and colleagues describe this as a suggestion from "individuals with impaired ionic magnesium absorption", and separately write, about organic and inorganic magnesium salts, that "clinical evidence directly comparing their absorption remains limited".1 In a mouse study (Ates and colleagues, Biological Trace Element Research, 2019), magnesium citrate, malate, acetyl taurate and glycinate were given by mouth at 45, 135 and 405 mg per 70 kg of elemental magnesium.7 The results the PubMed record summarises name magnesium acetyl taurate and magnesium citrate, not glycinate, and its authors report that dividing high doses "did not sufficiently increase tissue magnesium levels" in those mice.7
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~6 h
- Bioavailability
- 80%
- Typical dose
- 200–400 mg/day
- Route
- Oral
- Time to peak
- ~2 h
Sources in this part
The middle column of the table holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~6 h | A plasma half-life for magnesium glycinate was not identified in PubMed (three queries run); the 6-hour figure is the app's own. |
| Bioavailability | 80% | 23.5% absorption of a 100 mg dose of 26Mg-labeled magnesium diglycinate chelate, against 22.8% for magnesium oxide, in 12 patients with ileal resections.3 In 40 healthy adults given 375 mg of elemental magnesium, the plasma rise after magnesium bisglycinate was not significant at any time point.2 |
| Time to peak | ~2 h | Peak isotope enrichment occurred earlier after the chelate than after magnesium oxide, by a mean difference of 3.2 +/- 1.3 hours, in 12 patients with ileal resections; the PubMed record gives that difference, not an absolute time.3 |
The app lists a half-life of about 6 hours with a one-compartment model; a source figure for a magnesium glycinate half-life was not identified, so the app's figure is shown without a comparison. The app lists a bioavailability of 80%; Schuette and colleagues report 23.5% absorption from a 100 mg dose of 26Mg-labeled magnesium diglycinate chelate and 22.8% from magnesium oxide, in a group of patients with ileal resections who are at risk of poor magnesium absorption.3 Pajuelo and colleagues gave 40 healthy adults a single dose of 375 mg elemental magnesium in each of four products, one week apart, and drew plasma at 0, 1, 4 and 6 hours.2 Plasma magnesium rose after magnesium oxide by 7.1% at 1 hour and after magnesium citrate by 7.5% at 4 hours, but the rise after magnesium bisglycinate was not significant at 1, 4 or 6 hours.2 Between products, "no differences in the increased Mg levels in plasma were found between the tested products after 1 h or 4 h of oral intake (in all pair-wise comparisons)", and the areas under the curve did not differ significantly.2 The authors read their data as "suggesting that the intestinal absorption of Mg-BG is less efficient", and add that "different studies pointed out that a significant increase in Mg levels in plasma is not always achieved after the oral intake of supplements, most likely due to the differences in the pool of volunteers and/or methodologies".2 The app lists a time to peak of about 2 hours; the sources reviewed give a difference in peak timing against magnesium oxide, not an absolute peak time for magnesium glycinate.3
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Schuster and colleagues, Nature and Science of Sleep, 20251 | Randomised, double-blind, placebo-controlled, parallel; funded by the Institute of Food and One Health, Leibniz University Hannover1 | 155 randomised adults aged 18-65 with self-reported poor sleep quality; 153 in the primary analysis; 134 completed1 | Magnesium bisglycinate supplying 250 mg elemental magnesium a day, or placebo; 4 weeks1 | Insomnia Severity Index change -3.9 (95% CI -5.8 to -2.0) with magnesium bisglycinate against -2.3 (95% CI -4.1 to -0.4) with placebo, p = 0.049, small effect size; no significant difference in the other questionnaires1 |
| Pajuelo and colleagues, Nutrients, 20242 | Randomised, double-blind crossover; funded by Lubrizol Life Science, with Lubrizol employees among the authors2 | 40 healthy adults aged 20 to 552 | Single dose of 375 mg elemental magnesium in each of four products (oxide, citrate, bisglycinate, microencapsulated oxide), 7 days apart; plasma at 0, 1, 4 and 6 hours2 | Plasma rise after magnesium bisglycinate not significant at any time point; oxide +7.1% at 1 hour, citrate +7.5% at 4 hours; areas under the curve not significantly different between products; one volunteer left after adverse effects on magnesium bisglycinate2 |
| Schuette and colleagues, JPEN, 19943 | Double-blind randomised crossover; US federal grants3 | 12 patients with ileal resections3 | Single 100 mg dose of 26Mg-labeled magnesium diglycinate chelate or magnesium oxide3 | Absorption 23.5% with the chelate against 22.8% with magnesium oxide; in the four patients with the greatest impairment, 23.5% against 11.8%; peak enrichment earlier after the chelate (mean difference 3.2 +/- 1.3 hours); chelate better tolerated by all patients3 |
| Maddirevula and colleagues, Pulmonary Pharmacology and Therapeutics, 20265 | Randomised, double-blind, placebo-controlled; the authors declare no competing interests, and the PubMed record gives no funding statement5 | 224 adults (112 asthma, 112 COPD) with confirmed hypomagnesemia, in India5 | Magnesium glycinate 440 mg daily or placebo (n = 112 each) alongside standard therapy; 12 months5 | C-reactive protein change -0.97 mg/L in asthma and -3.42 mg/L in COPD against placebo; FEV1 +0.23 L (asthma) and +0.19 L (COPD); no serious adverse events; the PubMed record gives numbers for only some of the four primary outcomes5 |
| Mayo Clinic, registry entry NCT03564665, 2018 to 20214 | Randomised, single-blind (participant) placebo-controlled; sponsor Mayo Clinic4 | 40 enrolled; women with a history of invasive breast cancer, DCIS or LCIS and bothersome hot flashes4 | Magnesium glycinate 400 mg twice a day or placebo twice a day, 8 weeks4 | Primary outcome percent change in hot flash frequency; status completed; the entry gives no results data4 |
| Natural Calm Canada, registry entry NCT03353636, 20176 | Randomised five-period crossover, quadruple masked; sponsor Natural Calm Canada, whose entry states the aim of demonstrating the superiority of its own magnesium powder6 | 12 enrolled; healthy post-menopausal women aged 35 to 656 | Single doses of 150 mg elemental magnesium in each of four products (Natural Calm magnesium powder and three marketed forms, two of them magnesium bisglycinate powders), and a placebo6 | Primary outcomes serum and urine magnesium area under the curve; status completed; the entry gives no results data6 |
Deeper analysis: Schuster and colleagues, sleep trial, 2025
Schuster and colleagues (Leibniz University Hannover and Murdoch University) ran a two-arm, parallel-group, four-week, double-blind, placebo-controlled trial across Germany and registered it as DRKS00031494.1 Each capsule contained "893 mg of magnesium bisglycinate, corresponding to 125 mg of magnesium and 761.5 mg of glycine", giving a daily dose of 250 mg of magnesium and 1523 mg of glycine; 125 divided by 893 is about 14% magnesium by weight.1 The primary measure was the Insomnia Severity Index (ISI), with the other questionnaires as secondary measures, and the primary analysis followed the intention-to-treat principle.1 The authors report that the magnesium bisglycinate group had a significantly greater ISI reduction to week 4 ("-3.9 [95% CI: -5.8 to -2.0] vs -2.3 [95% CI: -4.1 to -0.4], respectively; p = 0.049"), and describe the effect size as small, "indicating a modest benefit".1 The per-protocol analysis of 134 participants gave "−5.0 (95% CI, −7.5 to −2.4)" with magnesium bisglycinate against "−3.1 (95% CI, −5.5 to −0.8)" with placebo (p = 0.035).1 Null and secondary results: "No statistically significant time × group interaction was observed in the other questionnaires", and the single-item sleep quality scale difference "did not reach statistical significance (p = 0.069)".1 The exploratory analysis suggested "notably greater improvements among participants reporting lower baseline dietary magnesium intake", measured with a non-validated single-question scale.1 Of those randomised, 65 on placebo and 69 on magnesium bisglycinate remained at week 4, and two placebo participants withdrew for stomach pain; the reasons for 11 placebo and 8 intervention withdrawals were unspecified.1 The paper states that there were "no reports of any serious adverse events"; 93% of participants reported none, and the adverse event table totals 7 events in the placebo group and 2 in the magnesium bisglycinate group.1 The paper's table note says "no participants discontinued the trial due to adverse events", which sits beside the text's account of two placebo withdrawals for stomach pain.1 Limitations in the authors' words: "The validity of the sleep-related outcomes is limited by the exclusive reliance on self-reported data without objective verification", and the week-4 mean score "remained in the subthreshold insomnia range, indicating that supplementation alone is unlikely to eliminate insomnia in many individuals".1 They add that "the use of an unvalidated questionnaire to assess dietary intake and the absence of biochemical markers of magnesium status raise the possibility that factors such as overall dietary quality or health status may have influenced the results", and that "fewer than 10% of participants provided complete entries" in the voluntary sleep diary.1 Funding and ties: the study "was funded by the Institute of Food and One Health, Leibniz University Hannover"; Adrian Lopresti "is the managing director of Clinical Research Australia, a contract research organization that receives research funding from nutraceutical companies", and the other authors declare no conflicts.1 Three of the four authors are affiliated with the Institute of Food and One Health that funded the study, and the paper states the research was conducted within the institute as part of an internal academic project.1 The supplement "was manufactured by Biogena, Salzburg, Austria"; the paper's funding and conflict statements do not name Biogena.1
Deeper analysis: Pajuelo and colleagues, absorption comparison, 2024
Pajuelo and colleagues (Bionos Biotech, Valencia, with Lubrizol Life Science, Nutrients, 2024) set out to test a microencapsulated magnesium oxide ingredient; magnesium bisglycinate was one of three comparators.2 Forty healthy adults aged 20 to 55 followed a low-magnesium diet, then received each product as an orosoluble powder with 375 mg of elemental magnesium, at 7-day intervals in random order.2 Plasma magnesium for the microencapsulated product rose "by 7.9%, 7.5%, and 8.8% after 1 h, 4 h, and 6 h", while the rise for magnesium bisglycinate was not significant at any time point.2 Secondary and null results: no pairwise differences between products at 1 or 4 hours, and no significant differences in the areas under the curve; at 6 hours the microencapsulated product's rise was 10.3% higher than magnesium oxide's.2 On a self-assessment questionnaire, "volunteers reported increased intestinal flow with MgO and Mg-C and increased stomach heaviness with Mg-BG and MgO", compared with the microencapsulated product.2 One volunteer "did not complete the study due to adverse effects upon the oral intake of Mg-BG" and was replaced, with that person's data not analysed.2 The authors write that "While studying populations with Mg deficiencies or increased demands could provide additional insights" and that "Larger-scale studies will be considered to further evaluate the tested products in different populations".2 Their conclusion describes the microencapsulated product as improving "the dynamics of Mg bioavailability" compared with other sources, "especially when compared to Mg bisglycinate, one of the gold standards for Mg supplementation".2 Funding and ties: "this study received funding from Lubrizol Life Science", two authors "were employed by Lubrizol Life Science" and three "were employed by Bionos Biotech SL"; the authors state "The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication."2
Deeper analysis: Schuette and colleagues, ileal resection trial, 1994
Schuette and colleagues (Department of Medicine, University of Chicago, JPEN, 1994) compared magnesium diglycinate chelate with magnesium oxide in patients who had ileal resections.3 Their stated background is that "Magnesium repletion is difficult to accomplish because of the cathartic action of most oral magnesium supplements at therapeutic doses", and that in vitro and in situ studies show the chelate "is absorbed in part as an intact dipeptide in the proximal small intestine".3 Across the group, "26Mg absorption was low but was not different for the two supplements (23.5% vs 22.8% for magnesium chelate and MgO, respectively)".3 Absorption was "substantially greater from the chelate (23.5% vs 11.8%" in the four patients with the greatest impairment of absorption from magnesium oxide, and the chelate "was better tolerated by all patients".3 The authors conclude that magnesium diglycinate "may be a good alternative to commonly used magnesium supplements in patients with intestinal resection".3 The PubMed record lists grants from the NIDDK, FDA and NCRR and names no industry sponsor; it contains no limitations statement.3
Registry entries and the lung disease trial
The Mayo Clinic entry NCT03564665 gives the status "COMPLETED", names Mayo Clinic as lead sponsor, and gives no results data; a PubMed query for magnesium glycinate and hot flashes returned 0 records.4 The Natural Calm Canada entry NCT03353636 states its objective as "to demonstrate the superiority of Natural Calm magnesium powder with respect to absorption when compared to three marketed forms of magnesium (two magnesium bisglycinate powders and magnesium citrate capsules)"; its lead sponsor is Natural Calm Canada, and it lists no results data.6 Maddirevula and colleagues report, in the PubMed record, reductions in C-reactive protein "(asthma: -0.97 mg/L, 95% CI -1.34 to -0.61" and "COPD: -3.42 mg/L, 95% CI -4.23 to -2.61" against placebo, and FEV1 gains of 0.23 L and 0.19 L, in adults with confirmed hypomagnesemia taking standard therapy.5 The record names TNF-α, IL-6 and IL-10 as primary outcomes but gives a number only for IL-10 (+2.8 pg/mL, 95% CI +0.61 to +4.99, p = 0.013).5
Doses reported in studies and on labels
The app lists a typical dose of 200 to 400 mg/day by mouth; its dose unit is mg/day and does not say whether the figure is elemental magnesium. A query of DailyMed for magnesium glycinate returned 13 labels, all multi-ingredient products, and no single-ingredient magnesium glycinate label was identified, so no label dose is given.
| Study or entry | Dose as reported | Frequency and length | People |
|---|---|---|---|
| Schuster and colleagues, 20251 | Magnesium bisglycinate supplying 250 mg elemental magnesium (and 1523 mg glycine) a day1 | Daily for 4 weeks, against placebo1 | 155 randomised adults reporting poor sleep1 |
| Pajuelo and colleagues, 20242 | 375 mg elemental magnesium as magnesium bisglycinate powder, with oxide, citrate and microencapsulated oxide as comparators2 | Single dose, plasma at 0, 1, 4 and 6 hours2 | 40 healthy adults2 |
| Schuette and colleagues, 19943 | 100 mg dose of 26Mg-labeled magnesium diglycinate chelate, against magnesium oxide3 | Single dose in a crossover3 | 12 patients with ileal resections3 |
| Maddirevula and colleagues, 20265 | Magnesium glycinate 440 mg daily; the record does not say whether this is elemental magnesium5 | Daily for 12 months, against placebo5 | 224 adults with asthma or COPD and hypomagnesemia5 |
| Mayo Clinic, NCT035646654 | 400 mg magnesium glycinate twice a day; the entry does not say whether this is elemental magnesium4 | Twice daily for 8 weeks, against placebo4 | 40 women with a history of invasive breast cancer, DCIS or LCIS and bothersome hot flashes4 |
| Natural Calm Canada, NCT033536366 | 150 mg elemental magnesium in a single oral dose, per product6 | Single doses in a five-period crossover6 | 12 post-menopausal women aged 35 to 656 |
Side effects reported
In the sleep trial, "There were no reports of any serious adverse events in the trial", and the adverse event table totals 7 events with placebo and 2 with magnesium bisglycinate (n = 76 and 77 in the table).1 In the 2024 absorption comparison, more volunteers reported "increased stomach heaviness with Mg-BG and MgO" than with the microencapsulated product, and one volunteer withdrew after adverse effects on magnesium bisglycinate.2 In the 1994 trial in patients with ileal resections, the chelate "was better tolerated by all patients" than magnesium oxide.3 The 2026 trial in hypomagnesemic asthma and COPD reports "no serious adverse events compared to placebo" over 12 months.5
Bloodwork and markers
The app lists no health markers to monitor for magnesium glycinate. The studies measured plasma magnesium (Pajuelo), the enrichment of an orally given 26Mg isotope (Schuette), serum and urine magnesium areas under the curve (the Natural Calm registry entry), and CRP, TNF-α, IL-6, IL-10, FEV1/FVC and serum magnesium (Maddirevula).2,3,5,6 Schuster and colleagues note that their trial lacked "biochemical markers of magnesium status" and name "serum magnesium or, preferably, 24-hour urinary magnesium excretion" as markers for future trials.1
Regulatory and anti-doping status
Sources in this part
The World Anti-Doping Agency's 2026 Prohibited List is valid from 1 January 2026, and the word magnesium does not occur in the text of the list retrieved (38,830 characters, including the sections through P1 beta-blockers).8 No single-ingredient magnesium glycinate label was identified in DailyMed, so no US label statement on its approval or labelled uses is given.
What is not known
Sources in this part
- A plasma half-life for magnesium glycinate was not identified in PubMed in three queries, so the app's 6-hour figure has no figure from the sources beside it.
- Results of the Mayo Clinic hot flash trial and the Natural Calm Canada absorption trial were not identified: both entries are marked completed and list no results data.
- Absorption data differ by population and method: 23.5% absorption in patients with ileal resections in 1994, and no significant plasma rise after magnesium bisglycinate in healthy adults in 2024.3,2
- The 2026 asthma and COPD trial was in people with confirmed hypomagnesemia; its results are not evidence about people with normal magnesium status.5
Frequently asked questions
What is the half-life of magnesium glycinate?
The app lists a half-life of about 6 hours. A plasma half-life for magnesium glycinate was not identified in PubMed in three queries, so no figure from the sources is given beside the app's.
What is the bioavailability of magnesium glycinate?
The app lists a bioavailability of 80%. Schuette and colleagues report 23.5% absorption of a 100 mg dose of 26Mg-labeled magnesium diglycinate chelate in 12 patients with ileal resections, against 22.8% for magnesium oxide.3 In 40 healthy adults given 375 mg of elemental magnesium, Pajuelo and colleagues saw no significant plasma rise at any time point after magnesium bisglycinate.2
Is magnesium glycinate banned by WADA?
The word magnesium does not occur in the text of the WADA 2026 Prohibited List retrieved for this review.8
What did the magnesium bisglycinate sleep trial show?
In 155 randomised adults reporting poor sleep, the Insomnia Severity Index change to week 4 was -3.9 with magnesium bisglycinate (250 mg elemental magnesium a day) against -2.3 with placebo, p = 0.049, with a small effect size.1 The other questionnaires showed no significant differences, the outcomes were self-reported, and the trial lasted 4 weeks.1
What is the time to peak of magnesium glycinate?
The app lists a time to peak of about 2 hours. Schuette and colleagues report that peak isotope enrichment came earlier after the chelate than after magnesium oxide by a mean of 3.2 +/- 1.3 hours in 12 patients with ileal resections, without an absolute peak time in the PubMed record.3
Does magnesium glycinate cause side effects?
In the 4-week sleep trial, no serious adverse events were reported, and the adverse event table totals 7 events with placebo and 2 with magnesium bisglycinate.1 In the 2024 absorption comparison, volunteers reported "increased stomach heaviness with Mg-BG and MgO" relative to a microencapsulated product, and one volunteer left the study after adverse effects on magnesium bisglycinate.2
How is magnesium glycinate absorbed?
Schuette and colleagues write that their data "support the suggestion that some portion of magnesium diglycinate is absorbed intact, probably via a dipeptide transport pathway", from a trial in 12 patients with ileal resections.3 Schuster and colleagues describe organic magnesium salts as possibly having "slightly higher bioavailability than inorganic forms", with direct clinical comparisons limited.1
What percentage of magnesium bisglycinate is elemental magnesium?
In the capsules used in the sleep trial, 893 mg of magnesium bisglycinate corresponded to 125 mg of magnesium, about 14% by weight.1
Has magnesium glycinate been tested for hot flashes?
A Mayo Clinic registry entry (NCT03564665) lists a randomised, single-blind trial of 400 mg of magnesium glycinate twice a day against placebo for 8 weeks in 40 women with a history of invasive breast cancer, DCIS or LCIS and bothersome hot flashes.4 The entry is marked completed and gives no results data.4
Guides, tools and comparisons
References
- Schuster J, Cycelskij I, Lopresti A, Hahn A. Magnesium Bisglycinate Supplementation in Healthy Adults Reporting Poor Sleep: A Randomized, Placebo-Controlled Trial. Nat Sci Sleep 2025;17:2027-2040. PMID 40918053
- Pajuelo D, Meissner JM, Negra T, Connolly A, Mullor JL. Comparative Clinical Study on Magnesium Absorption and Side Effects After Oral Intake of Microencapsulated Magnesium (MAGSHAPETM Microcapsules) Versus Other Magnesium Sources. Nutrients 2024;16(24). PMID 39770988
- Schuette SA, Lashner BA, Janghorbani M. Bioavailability of magnesium diglycinate vs magnesium oxide in patients with ileal resection. JPEN J Parenter Enteral Nutr 1994;18(5):430-5. PMID 7815675
- Mayo Clinic. Investigating Magnesium Glycinate in Structure/Function Role of Hot Flashes. ClinicalTrials.gov NCT03564665. NCT03564665
- Maddirevula MK, Rajanandh MG, Wesley B. Efficacy and safety of magnesium glycinate as add on therapy in hypomagnesemic asthma and chronic obstructive pulmonary disease patients: A randomised controlled study assessing inflammatory biomarkers. Pulm Pharmacol Ther 2026;95:102440. PMID 42633850
- Natural Calm Canada. Bioavailability of Magnesium Supplements. ClinicalTrials.gov NCT03353636. NCT03353636
- Ates M, Kizildag S, Yuksel O, et al. Dose-Dependent Absorption Profile of Different Magnesium Compounds. Biol Trace Elem Res 2019;192(2):244-251. PMID 30761462
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list